VYMI241115P71000
- 0.40
- -0.15-27.27%
Vanguard International High Dividend Yield Etf Newsroom
Vicinity Motor Shares Are Trading Lower After the Company Announced It Has Not Been Successful Renegotiating Terms With Royal Bank of Canada or Export Development Canada
Teva Launches First U.S. Generic Against Novartis Antidiarrheal Sandostatin LAR
Perspective Draws Buy at Truist on Radiopharma Potential
How to deploy a rate cut cycle? Top ten 'financial dividends and income' US stocks revealed, up more than 50% this year.
In a low-interest-rate environment, high dividends can still provide investors with stable cash flow and relatively robust returns, making it a long-term winning choice that can span cycles.
Novartis Lower as BofA Downgrades on Risks to Valuation
CIBC Maintains Neutral on Royal Bank of Canada, Raises Price Target to C$167
Novartis Licenses Gene Therapy Component From Voyager
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
Scotiabank Maintains Sector Outperform on Royal Bank of Canada, Raises Price Target to C$167
Royal Bank Of Canada Shares Are Trading Higher Following Better-than-expected Q3 Financial Results.
Royal Bank Of Canada Q3 EPS $2.38 Beats $2.16 Estimate, Sales $10.69B Beat $10.56B Estimate
Siemens Healthineers Seeks €200M Novartis Deal to Boost Cancer Imaging Business: FT
Barclays Maintains Equal-Weight on Royal Bank of Canada, Raises Price Target to C$150
Former CFO of Royal Bank of Canada sues previous employer for "spreading rumors of extramarital affair" in public statement, seeking 260 million yuan in compensation.
Royal Bank of Canada announced on April 5th of this year that CFO Nadine Au's contract has been terminated, alleging extramarital affairs within the company; Another executive at the bank was also dismissed on the same day; Both of them denied the accusation of extramarital affairs and sued the bank for defamation.
Siemens Non-GAAP EPS of €2.66, Revenue of €18.9B; Reaffirms FY24 Outlook
Earnings Summary: Novartis Beats Q2 Earnings Estimates; Raises 2024 Profit Forecast on Demand for New Drugs
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Core Operating Income Outlook
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Argus Research Maintains Buy on Royal Bank of Canada, Raises Price Target to $120
Novartis, Roche Facing Italy Antitrust Probe Over Lucentis Biosimilar